Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN501: Daratumumab Safety Study in Multiple Myeloma
NCT00574288Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2008
- Primary completion
- Jan 2015
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Mar 2008; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00574288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00574288.